Related Experiment Videos
Protein kinase C isoform diversity in preconditioning
D R Meldrum1, J C Cleveland, X Meng
1Department of Surgery, University of Colorado Health Sciences Center, Denver 80262, USA.
The Journal of Surgical Research
|April 1, 1997
Summary
Different protein kinase C (PKC) isoforms offer distinct myocardial protection. Activating specific PKC isoforms may provide targeted cardiac protection against ischemia-reperfusion injury, improving pH, function, and viability.
Area of Science:
- Cardiology
- Molecular Biology
- Biochemistry
Background:
- Protein kinase C (PKC) is a key intracellular effector in cardiac preconditioning.
- The specific roles of different PKC isoforms in myocardial protection are not fully understood.
Purpose of the Study:
- To investigate the relationship between the activation of unique PKC isoforms and specific aspects of endogenous myocardial protection (pH, function, viability).
Main Methods:
- Isolated rat hearts underwent ischemia-reperfusion (I/R).
- Hearts were treated with agonists activating specific PKC isoforms: phenylephrine (PE; delta and eta), adenosine (ADO; eta), or phorbol myristate acetate (PMA; delta).
- Myocardial protection was assessed by function (%RPP, CF), pH (31P NMR), and viability (CK leak).
Main Results:
- PMA (PKC delta) protected pH and viability but not function.
- ADO (PKC eta) protected function but not pH or viability.
- PE (PKC delta and eta) provided global protection against stunning, acidosis, and necrosis.
Conclusions:
- Distinct PKC isoforms are linked to specific protective aspects of the heart.
- Targeted activation of PKC isoforms could enable precise preconditioning-like myocardial protection.